摘要
背景:氟尿嘧啶缓释剂是目前常用的抗肿瘤缓释药物,具有良好的抗肿瘤作用。目的:探讨氟尿嘧啶缓释剂在进展期胃癌治疗中的作用效果。方法:应用文献检索的方法获取氟尿嘧啶缓释剂在胃癌治疗中应用的相关研究文献,对符合研究标准的文献进行深入的数据分析,文章选取氟尿嘧啶缓释剂预防肿瘤根治切除后复发和转移进行研究,对临床应用氟尿嘧啶缓释剂植入腹腔治疗的患者进行观察随访,通过观察患者的症状和体征、肿瘤标记物的表达变化、肿瘤组织的大小以及生存率等,明确氟尿嘧啶缓释剂在进展期胃癌治疗中的应用效果。结果与结论:进展期胃癌患者治疗中应用氟尿嘧啶缓释剂联合动脉灌注化疗辅助治疗后,患者的症状改善程度及肿瘤切除率明显提高,患者血清中肿瘤指标物CEA、CA19-9、CA72-4显著降低,肿瘤切除前后病理学比较显示化疗后肿瘤细胞的凋亡及坏死程度明显增加。应用氟尿嘧啶缓释剂还能够降低肿瘤局部转移和复发,提高患者生存率。
BACKGROUND:Fluorouracil sustained-release agent is a commonly used anti-cancer sustained-release drug, which has a good anti-tumor effect.
OBJECTIVE:To explore the effect of fluorouracil sustained-release agent in the treatment of gastric cancer. METHODS:Literatures concerning the effect of fluorouracil sustained-release agent in the treatment of gastric cancer were retrieved and analyzed. In the paper, we investigated the preventive effect of fluorouracil sustained-release agent against tumor recurrence and metastasis after radical resection, and fol owed up the patients who underwent clinical peritoneal implantation of fluorouracil sustained-release agent. We could determine the effect of fluorouracil sustained-release agent in the treatment of advanced gastric cancer by observing the patient’s symptoms and signs, expression of tumor markers, tumor size and survival rate.
RESULTS AND CONCLUSION:After combination therapy of fluorouracil sustained-release agent and arterial infusion chemotherapy adjuvant therapy, the patient’s symptoms and tumor resection rate were significantly improved. The levels of CEA, CA19-9, CA72-4 in the serum of patients significantly reduced, while the apoptosis and necrosis of tumor cells significantly increased. Fluorouracil sustained-release agent could also reduce tumor metastasis and local recurrence, and improve patient survival.
出处
《中国组织工程研究》
CAS
CSCD
2013年第42期7469-7474,共6页
Chinese Journal of Tissue Engineering Research
关键词
消化系统疾病
胃疾病
肿瘤
各部位
消化系统肿瘤
胃肿瘤
digestive system diseases
stomach diseases
neoplasms by site
digestive system neoplasms
stomach neoplasms